Diagnostic value of serum brain-derived neurotrophic factor (BDNF), neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), plasma viscosity (PV) as well as fibrinogen (FIB) in acute cerebral infarction patients.

BACKGROUND

To explore the Diagnostic value of serum brain-derived neurotrophic factor (BDNF), neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), plasma viscosity (PV) as well as fibrinogen (FIB) in patients receiving butylphthalide and sodium chloride injection in combination with atorvastatin calcium in acute cerebral infarction patients.

METHODS

Eighty ACI patients treated at our hospital between January 2022 and January 2024 were included as study participants, followed by divided into the control group (CG) and study group (SG). The CG was given atorvastatin calcium tablets. Based on the CG, the SG received a butylphthalide sodium chloride injection. The clinical efficacy, neurological impairment, daily living ability, hemorheological indicators, neurobiochemical indicators, and occurrence of adverse reactions in the two groups were compared.

RESULTS

Compared to the CG, the SG's total effective clinical effect rate was significantly higher (P<0.05). After therapy, the NIHSS score in the SG showed a significant reduction relative to the CG, and the BI score in the SG was significantly higher relative to the CG (P<0.05). The whole blood high shear viscosity, whole blood low shear viscosity, PV, HCT, and FIB levels in the SG, were significantly reduced relative to the CG (P< 0.05). The improvements of BDNF NSE, and GFAP levels in the SG were significantly superior to the CG (P< 0.05). No significant differences in adverse reactions were observed between the two groups (P>0.05).

CONCLUSIONS

The combination of butylphthalide sodium chloride injection and atorvastatin calcium tablets significantly improved clinical outcomes in ACI patients by improving neurological function, daily living ability, cerebral hemodynamics, and neurobiochemical markers. This therapeutic regimen offers a promising approach to ACI management and warrants further clinical promotion. The novel aspect of this study lies in its comprehensive evaluation of both neurological and hemodynamic improvements, highlighting the potential synergistic benefits of this combined therapy.